


REMARKS


Claims 1-36 and 42-47 are pending in this application. The Examiner has required restriction to one of four (4) groups. In response to such restriction Applicants wish to proceed as follows.

Applicants elect with traverse Group I (claims 1-30, 36 and 42-44), drawn to a compound or composition which contains at least one compound of formula (I)



according to claim 1, for prosecution on the merits.

Applicants elect Example 2, page 59 (PCT specification) as a single invention in accordance with 37 CFR 1.499. Example 2 is set forth as 8-[3-[3-(3,4-dichlorophenyl)-1-(2-furoyl)pyrrolidin-3-yl]propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one



It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

/Bonnie L. Deppenbrock/
Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 8 June 2006

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-1577
Facsimile: 919-483-7988